What was the primary driver of the significant sales growth in the first quarter of 2004?

The primary drivers of the 17.7% worldwide sales increase were strong performance across all three segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The Medical Devices & Diagnostics segment, in particular, experienced substantial growth, with the CYPHER drug-eluting stent being a major contributor. Additionally, favorable foreign currency exchange rates significantly boosted international sales.

How did the company's profitability change compared to the previous year?

Johnson & Johnson's profitability improved significantly in the first quarter of 2004. Net earnings increased to $2.49 billion from $2.07 billion in the same period of 2003. Consequently, diluted earnings per share also rose to $0.83 from $0.69 year-over-year.

What is the company's stance on ongoing legal proceedings and their potential impact?

The company acknowledges numerous ongoing legal proceedings, including product liability litigation (such as the PROPULSID cases), patent infringement disputes, and investigations related to marketing practices. While the company is vigorously defending itself in many of these matters and has accrued amounts for potential liabilities, it states that the ultimate outcome is uncertain. However, management believes that, after considering existing accruals and insurance, the resolution of these legal proceedings is not expected to have a material adverse effect on the company's consolidated financial position, although it could impact results of operations and cash flows in specific periods.

Has Johnson & Johnson returned capital to shareholders, and if so, how?

Yes, Johnson & Johnson has continued its commitment to returning capital to shareholders. In the first quarter of 2004, the company increased its regular quarterly cash dividend by 17.1% to $0.24 per share. Additionally, the company repurchased $407 million of its common stock during the quarter.

JNJ 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Johnson & Johnson (JNJ) reported strong first-quarter 2004 results, with worldwide sales increasing by 17.7% year-over-year to $11.6 billion. This growth was driven by robust performance across all three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Net earnings saw a significant increase to $2.49 billion, or $0.84 per share (basic), up from $2.07 billion, or $0.70 per share in the prior year's first quarter. The company also demonstrated a commitment to shareholder returns by increasing its quarterly cash dividend and continuing its share repurchase program. The positive financial performance was supported by favorable currency exchange rates, which contributed significantly to international sales growth. The Medical Devices and Diagnostics segment, in particular, showed exceptional growth, largely due to the strong performance of the CYPHER drug-eluting stent. While facing ongoing legal proceedings and patent litigation, the company expressed confidence in its ability to manage these issues and believes they will not have a material adverse effect on its overall financial position.

Key Highlights

1Worldwide sales increased 17.7% to $11.6 billion in Q1 2004 compared to Q1 2003.
2Net earnings rose to $2.49 billion ($0.84/share basic) from $2.07 billion ($0.70/share basic) in the prior year.
3All three business segments (Consumer, Pharmaceutical, Medical Devices & Diagnostics) experienced significant sales growth.
4The Medical Devices and Diagnostics segment saw a 22.9% sales increase, boosted by the CYPHER drug-eluting stent.
5International sales grew by 21.8%, aided by a favorable currency impact of 14.0%.
6The company increased its quarterly cash dividend by 17.1% to $0.24 per share.
7Cash flow from operations increased by $0.6 billion to $2.7 billion.

JOHNSON & JOHNSON Quarterly Report for Q1 Ended Mar 28, 2004

Summary

Key Highlights

Frequently Asked Questions